Sitemap - 2023 - Mendelspod

Kevin Davies on Gene Therapy in 2023

History and State of Proteomics 2023 with John Yates

Ukrainian American Biotech CEO on the War in Ukraine

Will the Precision Medicine Industry Bounce Back?

Seasons Greetings, Fans of Mendelspod!

New Philosophy of Biology Series on PBS: A Preview with Host Robert Lawrence Kuhn

Mapping the Meta Proteome: John Shon, CTO, Serimmune

Supercharged Killer Cells Effective Against Alzheimer’s: Paul Song, CEO, NKGen Biotech

Chris Hall and Rich Chen of Personalis on Next Gen MRD Testing

Thank you. We're getting close!

State of Sequencing 2023: Shawn Baker and Keith Robison

Newborn Sequencing 2023 Part II: What Evidence Is Enough?

Zack Abbott on Engineered Probiotics and GMOs

Lincoln Nadauld on the State of Precision Medicine in 2023

Nothing Is "Undruggable:" Alex Federation, CEO, Talus Bio

Mass Spec Advances in a New Age of Proteomics: Rosy Lee, Thermo Fisher Scientific

Theral's Picks: The FDA Moves (Again) to Regulate LDTs

This Is Very Cool: Treating Cancer with Sound

The Future of Clinical Proteomics with Jenny Van Eyk and Daniel Hornburg

The State of Newborn Sequencing in 2023: A Panel Discussion

Elinor Karlsson on Darwin’s Ark

Long DNA for Difficult Applications: Dan Lin-Arlow, CEO, Ansa Biotech

New Illumina CEO, Venter Book, and New Yorker Takes on He Jiankui

Next Gen CRISPR Therapies with Trevor Martin, CEO of Mammoth Biosciences

13th Season Opener: Mike Snyder on Microsampling and Multi-Omic Profiling

Addressing Racial Bias in Healthcare AI: Elliott Green of Dandelion Health

An Update on the GUARDIAN Newborn Sequencing Study with Wendy Chung

Gene Patent Decision at 10 Years, State of Genetic Testing with Ellen Matloff, My Gene Counsel

Proteomics Bigger than Genomics, It’s Just Taking Time, Says Jeff Hawkins, CEO, Quantum-SI

Biden, AI, and DeSci: John Cumbers Previews SynBioBeta 2023

Proteomics Today Where Genomics Was in the 80s: Margaret Donovan and Asim Siddiqui of Seer on Landmark Study

Is This New Platform an Answer to the Reproducibility Crisis? with Guy Rohkin

Elegen Pioneers Long DNA Subindustry with CEO Matt Hill

Nevermind the $200 Genome, Element CEO Molly He Says Core Chemistry Capable of Much More

3D Genomics Solves Cancer Case Where Sequencing Came Up Short: Anthony Schmitt, Arima Genomics

New Spatial Company Maps Cell Surface Proteome without Imaging

John Greally on His Latest Review of Epigenomics

President of ASHG on Eugenics Apology, Diversity Initiative

23andMe Launches New Personalized Healthcare Initiative with Amy Sturm

Converting Digital to Biological: John Gill, Telesis Bio

50% Not Tested: Precision Oncology with Jerome Madison, Invitae

Paul Freemont on Synthetic Biology in the UK